Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

Journal of Experimental Medicine

Volumn 201, Issue 2, 2005, Pages 249-257

  Lurquin, Christophe ^a,b   Lethé, Bernard ^a,b   De Plaen, Etienne ^a,b   Corbière, Véronique ^a   Théate, Ivan ^a,b   Van Baren, Nicolas ^a,b   Coulie, Pierre G ^a   Boon, Thierry ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN 1;

ARTICLE; CANCER INVASION; CASE REPORT; CELL CLONING; DNA EXTRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; SKIN METASTASIS; T LYMPHOCYTE; TUMOR CELL; TUMOR REJECTION; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 13244273592     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041378     Document Type: Article

References (18)

1. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethé, E. De Plaen, T. Velu, and P.G. Coulie. 2004. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201:241-248.
2. Karanikas, V., C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethé, T. Connerotte, V. Corbière, M.-A. Demoitié, D. Liénard, et al. 2003. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171:4898-4904.
3. Lennon, G.P., J.E. Sillibourne, E. Furrie, M.J. Doherty, and R.A. Kay. 2000. Antigen triggering selectively increases TCRBV gene transcription. J. Immunol. 165:2020-2027.
4. Davies, H., G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954.
5. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
6. Wang, H.Y., D.A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kiniwa, E.M. Shevach, and R.F. Wang. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 20:107-118.
7. Terabe, M., S. Matsui, J.M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
8. Gorelik, L., and R.A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7:1118-1122.
9. + T helper cells. J. Exp. Med. 196:255-260.
10. Fantini, M.C., C. Becker, G. Monteleone, F. Pallone, P.R. Galle, and M.F. Neurath. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149-5153.
11. Fallarino, F., U. Grohmann, K.W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M.L. Belladonna, M.C. Fioretti, M.L. Alegre, and P. Puccetti. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4:1206-1212.
12. Uyttenhove, C., L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274.
13. Munn, D.H., M.D. Sharma, D. Hou, B. Baban, J.R. Lee, S.J. Antonia, J.L. Messina, P. Chandler, P.A. Koni, and A.L. Mellor. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114:280-290.
14. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA. 101:14631-14638.
15. Boon, T., and B. Van den Eynde. 2003. Tumour immunology. Curr. Opin. Immunol. 15:129-130.
16. Dudley, M.E., J.R. Wunderlich, P.P. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
17. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040-1052.
18. Benitez, R., D. Godelaine, M.A. Lopez-Nevot, F. Brasseur, P. Jiménez, M. Marchand, M.R. Oliva, N. van Baren, T. Cabrera, G. Andry, et al. 1998. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 52:520-529.